# Inventiva

Canonical page: https://technooptimist.io/companies/inventiva
French biotech developing lanifibranor, a daily pill that switches on all three PPAR fat-metabolism receptors, for MASH with liver scarring. Its phase 3 NATiV3 reads out in Q4 2026.

## In brief

- NATiV3: 1,009-patient phase 3, last 72-week visit done Sep 2026; topline Q4 2026.
- If positive: US filing H1 2027 for accelerated approval, possible 2028 launch.
- €233.9M cash at 30 Jun 2026; runway into Q2 2027 (early 2028 with conditional debt).

## Facts

- Headquarters: FR
- Status: public
- Website: https://inventivapharma.com
- Frontiers: [Biotech](https://technooptimist.io/biotech.md) (Fatty liver (MASH))

## Programs

- [Lanifibranor](https://technooptimist.io/biotech/lanifibranor.md) (Biotech): Pilot; next: NATiV3 topline results (Q4 2026). Phase 3 NATiV3 fully dosed; topline due Q4 2026, US filing planned H1 2027 if positive.

## Upcoming

- **2027**: US NDA submission (if positive) (Lanifibranor)

## Latest updates

- **28 Sep 2026**: Inventiva: last NATiV3 patient completes 72 weeks; lanifibranor topline on track for Q4 2026. On its Q2 2026 call, Inventiva said the final NATiV3 patient finished the 72-week visit in September and topline results remain due in Q4 2026. ([our story](https://technooptimist.io/stories/inventiva-last-nativ3-patient-completes-72-weeks-lanifibranor-topline-657779d3.md) · [original source](https://www.marketbeat.com/instant-alerts/transcript-inventiva-q2-earnings-call-highlights-2026-09-28/))
- **1 Apr 2025**: Inventiva completes enrollment of its 1,009-patient phase 3 NATiV3 trial of lanifibranor in MASH. Inventiva finished randomising patients into NATiV3, the phase 3 trial of its daily pan-PPAR pill in MASH with moderate to advanced liver scarring. ([our story](https://technooptimist.io/stories/inventiva-completes-enrollment-of-its-1-009-patient-phase-3-nativ3-1ad9d765.md) · [original source](https://www.biospace.com/press-releases/inventiva-announces-completion-of-enrollment-in-the-phase-3-nativ3-clinical-trial-of-lanifibranor-in-patients-with-mash-and-advanced-fibrosis))

## People

- Andrew Obenshain, Chief Executive Officer

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.